• Menu
  • Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Before Header

Michelle's blog

Food allergy and food intolerance, freefrom foods, electrosensitivity, this and that...

  • Home
  • Blog
  • About
  • FreeFrom Food Awards
  • Foods Matter
  • Walks & Gardens
  • Salon Music
  • Home
  • Blog
  • About
  • FreeFrom Food Awards
  • Foods Matter
  • Walks & Gardens
  • Salon Music

Good news for those with peanut allergy

21/12/2020 //  by Michelle Berridale Johnson//  Leave a Comment

The news may be grim on the virus front but there have been two bits of good news this month for those with peanut allergy.

Earlier in the month The Journal of Allergy and Immunology: In Practice reported on on a trial which demonstrated that peanut oral immunotherapy is still effective after one year of maintenance in children from 7 months to 6 years old.

A total of 117 of the 161 eligible patients completed the trial and received the follow-up. Among them, 92 (78.6%) were able to tolerate a cumulative peanut protein dose of 4,000mg – around 28 peanuts. A total of 115 (98.3%) tolerated a cumulative 1,000mg dose (7 peanuts). This would most certainly protect them against accidental peanut exposures – thus easing greatest concern of the parents of peanut allergic children.

Worth noting was the fact that adrenaline/epinephrine was only needed by two participants during the maintenance phase, only one patient needed to go to the emergency department due to an allergic reaction and only 10.5% of participants experienced any allergic reactions at all.

And then today I received a press release announcing that Aimmune Therapeutics’ PALFORZIA drug has now received approval for use across Europe. PALFORZIA, to quote the press release is:

‘…a complex biologic drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research. With OIT, the specific allergenic proteins are ingested initially in very small quantities, followed by incrementally increasing amounts, that can result in the ability to mitigate allergic reactions to the allergen over time. PALFORZIA is a rigorously developed, pharmaceutical-grade OIT for peanut allergy with a well-defined allergen profile to assure the consistency of every dose, from 0.5 mg (equivalent to 1/600th of a peanut) to 300 mg.’

PALFORZIA has undergone very similar trials to those reported in the JACI with very similar outcomes. For more information on the PALISADE trial see the New England Journal of Medicine here and for the ARTEMIS trial see PubMed here.

“Results from landmark Phase 3 clinical trials have shown more than half of patients treated with PALFORZIA were able to tolerate the equivalent of seven to eight peanut kernels after up to nine months of treatment. These compelling data highlight its potential to mitigate against severe allergic reactions, including anaphylaxis in the event of unintended exposure to peanut protein,” said Prof. George du Toit, Professor of Paediatric Allergy at Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust.

However, while this is very good news for the long term treatment and management of peanut (and possibly other) allergies, those with peanut allergies (and parents of peanut allergic children) must remember that the treatment ‘is not intended for, and does not provide, immediate relief of allergic symptoms….’ It should not be used for emergency treatment of allergic reactions when adrenaline should always be available and be used.

close

Check your inbox or spam folder to confirm your subscription.

Category: Allergies, Peanut allergyTag: Aimmune Therapeutics, Aimmune Therapies PALFORZIA, ARTEMIS peanut allergy trial, OIT for peanut allergy, Oral immunotherapy, PALFORZIA, PALISADE peanut allergy trial, Peanut/treenut allergy, Prof. George du Toit, The Journal of Allergy and Immunology: In Practice

Previous Post: « Is it time to subject Vitamin C to serious scientific scrutiny?
Next Post: Happy, if distanced, Christmas! »

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Recent Posts

  • Homeopathy – a second string to our vaccination bow?
  • Sad, sad news
  • Are COVID vaccines safe for those with allergies?
  • Disastrous Brexit fallout for medical cannabis users
  • The trouble about gluten-free oats

Search this blog

ARCHIVES

Blogroll

  • Allergy Insight
  • Better brains, naturally
  • For Ever FreeFrom
  • Free From (gluten)
  • Freefrom Food Awards
  • Gluten-free Mrs D
  • Natural Health Worldwide
  • Pure Health Clinic
  • Skins Matter
  • The Helminthic Therapy Wiki
  • Truly Gluten Free
  • What Allergy?

TOPICS

The trouble about gluten-free oats

Oats are delicious – oats are nutritious – they contain high levels of vitamins, minerals and antioxidants and are an excellent source of fibre – they do not contain the protein gliadin, the gluten fraction that coeliacs need to avoid – they add texture to gluten free baking and are easy to cook with. Few …

Happy, if distanced, Christmas!

After this very strange and, for many people, horribly difficult year I wanted to wish you all a very peaceful, safe, healthy and hopefully happy Christmas. And offer you a little allergic chortle. Those of you who used to receive the FoodsMatter magazine will remember all of Christopher’s wonderful allergy related cartoons – the caption …

Good news for those with peanut allergy

The news may be grim on the virus front but there have been two bits of good news this month for those with peanut allergy. Earlier in the month The Journal of Allergy and Immunology: In Practice reported on on a trial which demonstrated that peanut oral immunotherapy is still effective after one year of …

Is it time to subject Vitamin C to serious scientific scrutiny?

Ever since 1970 when the Nobel Laureate Linus Pauling claimed that gram dose vitamin C supplementation could prevent and alleviate the common cold, the argument has rumbled on – how effective can vitamin C supplementation be for respiratory infections both mild (such as the common cold) or more acute (pneumonia and, maybe, COVID19). The evidence …

Share a meal

Yes, indeed – what a lovely thing to be able to do – and one that we have been deprived of for all too long. But, we don’t have to be. Over lockdown my good friend Sarah Stacey, who lives in a tiny village in Dorset, started cooking meals for a poorly neighbour. Talking to …

The importance of nutrition in children’s food

A few weeks ago I posted about our revamped Child and Teen Friendly Food category in this year’s FreeFrom Food Awards in which we are trying to tease out what children really think about the nutritional content of their food. So I was especially interested in an alert from FAB (Food and Behaviour Research) about …

Copyright © 2021 · Michelle's Blog · Michelle Berridale Johnson · Site design by DigitalJen·